STOCK TITAN

[8-K] Vera Therapeutics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

SMX (Security Matters) PLC has approved a 1-for-7 reverse stock split of its ordinary shares, effective at the open of trading on 7 Aug 2025 on the Nasdaq Capital Market. The shares will continue to trade under ticker SMX, but with a new CUSIP (G8267K2174) and ISIN (IE000TB5RTG4).

The split will reduce outstanding shares from ~9 million to ~1 million; every seven pre-split shares with a par value of $0.000000000000041 will convert into one post-split share with a par value of $0.000000000000287. Fractional entitlements will be aggregated and sold on the open market, with cash proceeds distributed to affected holders.

All outstanding options, warrants (incl. SMXWW) and other convertible securities will be proportionally adjusted. An amended constitution reflecting the new par value is filed as Exhibit 1.1, and the related press release is filed as Exhibit 99.1.

No additional shareholder vote was required because a May 2 2025 resolution had already authorized the board to consolidate or divide share classes at its discretion.

SMX (Security Matters) PLC ha approvato un raggruppamento azionario 1 per 7 delle sue azioni ordinarie, che entrerà in vigore all'apertura delle contrattazioni il 7 agosto 2025 sul Nasdaq Capital Market. Le azioni continueranno a essere negoziate con il ticker SMX, ma con un nuovo CUSIP (G8267K2174) e ISIN (IE000TB5RTG4).

Il raggruppamento ridurrà le azioni in circolazione da circa 9 milioni a circa 1 milione; ogni sette azioni pre-raggruppamento con un valore nominale di $0,000000000000041 saranno convertite in una azione post-raggruppamento con valore nominale di $0,000000000000287. Le frazioni di azioni saranno aggregate e vendute sul mercato aperto, con i proventi in contanti distribuiti ai titolari interessati.

Tutte le opzioni, warrant (incluso SMXWW) e altre obbligazioni convertibili in circolazione saranno adeguate proporzionalmente. Una costituzione modificata che riflette il nuovo valore nominale è depositata come Esibizione 1.1, e il comunicato stampa correlato è depositato come Esibizione 99.1.

Non è stato necessario un ulteriore voto degli azionisti poiché una delibera del 2 maggio 2025 aveva già autorizzato il consiglio a consolidare o dividere le classi azionarie a sua discrezione.

SMX (Security Matters) PLC ha aprobado una consolidación inversa de acciones 1 por 7 de sus acciones ordinarias, que entrará en vigor al inicio de la negociación el 7 de agosto de 2025 en el Nasdaq Capital Market. Las acciones seguirán cotizando bajo el símbolo SMX, pero con un nuevo CUSIP (G8267K2174) y ISIN (IE000TB5RTG4).

La consolidación reducirá las acciones en circulación de aproximadamente 9 millones a aproximadamente 1 millón; cada siete acciones previas a la consolidación con un valor nominal de $0.000000000000041 se convertirán en una acción posterior a la consolidación con un valor nominal de $0.000000000000287. Las fracciones resultantes se agruparán y venderán en el mercado abierto, y los ingresos en efectivo se distribuirán a los titulares afectados.

Todas las opciones, warrants (incluido SMXWW) y otros valores convertibles en circulación se ajustarán proporcionalmente. Se ha presentado una constitución enmendada que refleja el nuevo valor nominal como Exposición 1.1, y el comunicado de prensa relacionado se ha presentado como Exposición 99.1.

No se requirió una votación adicional de los accionistas porque una resolución del 2 de mayo de 2025 ya había autorizado a la junta a consolidar o dividir las clases de acciones a su discreción.

SMX (Security Matters) PLC는 1대 7 액면병합을 승인했으며, 이는 2025년 8월 7일 나스닥 캐피털 마켓 거래 시작 시점부터 효력이 발생합니다. 주식은 계속해서 SMX라는 티커로 거래되지만, 새로운 CUSIP (G8267K2174)과 ISIN (IE000TB5RTG4)이 부여됩니다.

이번 병합으로 발행 주식 수가 약 900만 주에서 약 100만 주로 감소하며, 병합 전 7주당 액면가 $0.000000000000041인 주식이 병합 후 1주당 액면가 $0.000000000000287인 주식 1주로 전환됩니다. 소수 주식은 모아져 공개 시장에서 매각되며, 현금 수익은 해당 주주들에게 배분됩니다.

모든 미결제 옵션, 워런트(예: SMXWW 포함) 및 기타 전환 증권도 비례하여 조정됩니다. 새로운 액면가를 반영한 개정 정관은 증거자료 1.1로 제출되었으며, 관련 보도자료는 증거자료 99.1로 제출되었습니다.

2025년 5월 2일 결의안으로 이사회가 자율적으로 주식 종류를 통합하거나 분할할 권한을 이미 부여받아 추가 주주 투표는 필요하지 않았습니다.

SMX (Security Matters) PLC a approuvé un regroupement d'actions inversé au ratio de 1 pour 7 de ses actions ordinaires, effectif à l'ouverture des marchés le 7 août 2025 sur le Nasdaq Capital Market. Les actions continueront d'être négociées sous le symbole SMX, mais avec un nouveau CUSIP (G8267K2174) et ISIN (IE000TB5RTG4).

Ce regroupement réduira le nombre d'actions en circulation d'environ 9 millions à environ 1 million ; chaque sept actions avant regroupement, d'une valeur nominale de 0,000000000000041 $, sera converti en une action après regroupement, d'une valeur nominale de 0,000000000000287 $. Les fractions d'actions seront regroupées et vendues sur le marché ouvert, les liquidités issues de la vente étant distribuées aux détenteurs concernés.

Toutes les options, bons de souscription (y compris SMXWW) et autres titres convertibles en circulation seront ajustés proportionnellement. Une constitution modifiée reflétant la nouvelle valeur nominale est déposée en tant qu'Exhibit 1.1, et le communiqué de presse associé en tant qu'Exhibit 99.1.

Aucun vote supplémentaire des actionnaires n'était nécessaire car une résolution du 2 mai 2025 avait déjà autorisé le conseil d'administration à consolider ou diviser les catégories d'actions à sa discrétion.

SMX (Security Matters) PLC hat eine Aktienzusammenlegung im Verhältnis 1 zu 7 seiner Stammaktien genehmigt, die ab Handelsbeginn am 7. August 2025 am Nasdaq Capital Market wirksam wird. Die Aktien werden weiterhin unter dem Ticker SMX gehandelt, erhalten jedoch eine neue CUSIP (G8267K2174) und ISIN (IE000TB5RTG4).

Die Zusammenlegung wird die ausstehenden Aktien von etwa 9 Millionen auf etwa 1 Million reduzieren; jeweils sieben Aktien vor der Zusammenlegung mit einem Nennwert von $0,000000000000041 werden in eine Aktie nach der Zusammenlegung mit einem Nennwert von $0,000000000000287 umgewandelt. Bruchteile werden gesammelt und am offenen Markt verkauft, die Erlöse werden an die betroffenen Inhaber ausgezahlt.

Alle ausstehenden Optionen, Warrants (einschließlich SMXWW) und andere wandelbare Wertpapiere werden anteilig angepasst. Eine geänderte Satzung, die den neuen Nennwert widerspiegelt, ist als Anlage 1.1 eingereicht, die zugehörige Pressemitteilung als Anlage 99.1.

Eine zusätzliche Abstimmung der Aktionäre war nicht erforderlich, da eine Resolution vom 2. Mai 2025 den Vorstand bereits ermächtigt hatte, Aktienklassen nach eigenem Ermessen zusammenzulegen oder zu teilen.

Positive
  • Retains Nasdaq listing by likely boosting share price above minimum bid.
  • Reduces share count by ~88%, simplifying capital structure and potentially easing future capital raises.
Negative
  • Reverse splits often signal sustained share-price weakness, which can weigh on investor sentiment.
  • Post-split float of ~1 M shares may reduce liquidity and increase price volatility.

Insights

TL;DR: Reverse split preserves Nasdaq listing but signals price weakness; share count falls 88%, dilutive instruments adjusted proportionally.

The 7-for-1 split should lift the per-share price above Nasdaq’s minimum bid requirement, reducing delisting risk. While mechanically neutral, reverse splits often follow sustained price declines and can be perceived negatively by investors. Post-split float shrinks to ~1 M shares, which may heighten volatility and hinder liquidity. Warrants (SMXWW) and other derivatives will re-price, so economic value for holders is unchanged. No operational or fundamental data were disclosed, leaving the long-term outlook unaffected. Impact: neutral to mildly negative.

TL;DR: Board used prior mandate to act swiftly; governance process complies with Irish law, no shareholder dilution beyond split mechanics.

Because shareholders pre-authorized share consolidation on 2 May 2025, the board could execute the split without further vote, demonstrating procedural efficiency. The filing also amends the constitution to align par value, ensuring statutory clarity. No fractional shares will be issued, a standard market-friendly provision that avoids administrative complexity. Overall, governance execution appears sound, though investor sentiment may hinge on post-split trading performance.

SMX (Security Matters) PLC ha approvato un raggruppamento azionario 1 per 7 delle sue azioni ordinarie, che entrerà in vigore all'apertura delle contrattazioni il 7 agosto 2025 sul Nasdaq Capital Market. Le azioni continueranno a essere negoziate con il ticker SMX, ma con un nuovo CUSIP (G8267K2174) e ISIN (IE000TB5RTG4).

Il raggruppamento ridurrà le azioni in circolazione da circa 9 milioni a circa 1 milione; ogni sette azioni pre-raggruppamento con un valore nominale di $0,000000000000041 saranno convertite in una azione post-raggruppamento con valore nominale di $0,000000000000287. Le frazioni di azioni saranno aggregate e vendute sul mercato aperto, con i proventi in contanti distribuiti ai titolari interessati.

Tutte le opzioni, warrant (incluso SMXWW) e altre obbligazioni convertibili in circolazione saranno adeguate proporzionalmente. Una costituzione modificata che riflette il nuovo valore nominale è depositata come Esibizione 1.1, e il comunicato stampa correlato è depositato come Esibizione 99.1.

Non è stato necessario un ulteriore voto degli azionisti poiché una delibera del 2 maggio 2025 aveva già autorizzato il consiglio a consolidare o dividere le classi azionarie a sua discrezione.

SMX (Security Matters) PLC ha aprobado una consolidación inversa de acciones 1 por 7 de sus acciones ordinarias, que entrará en vigor al inicio de la negociación el 7 de agosto de 2025 en el Nasdaq Capital Market. Las acciones seguirán cotizando bajo el símbolo SMX, pero con un nuevo CUSIP (G8267K2174) y ISIN (IE000TB5RTG4).

La consolidación reducirá las acciones en circulación de aproximadamente 9 millones a aproximadamente 1 millón; cada siete acciones previas a la consolidación con un valor nominal de $0.000000000000041 se convertirán en una acción posterior a la consolidación con un valor nominal de $0.000000000000287. Las fracciones resultantes se agruparán y venderán en el mercado abierto, y los ingresos en efectivo se distribuirán a los titulares afectados.

Todas las opciones, warrants (incluido SMXWW) y otros valores convertibles en circulación se ajustarán proporcionalmente. Se ha presentado una constitución enmendada que refleja el nuevo valor nominal como Exposición 1.1, y el comunicado de prensa relacionado se ha presentado como Exposición 99.1.

No se requirió una votación adicional de los accionistas porque una resolución del 2 de mayo de 2025 ya había autorizado a la junta a consolidar o dividir las clases de acciones a su discreción.

SMX (Security Matters) PLC는 1대 7 액면병합을 승인했으며, 이는 2025년 8월 7일 나스닥 캐피털 마켓 거래 시작 시점부터 효력이 발생합니다. 주식은 계속해서 SMX라는 티커로 거래되지만, 새로운 CUSIP (G8267K2174)과 ISIN (IE000TB5RTG4)이 부여됩니다.

이번 병합으로 발행 주식 수가 약 900만 주에서 약 100만 주로 감소하며, 병합 전 7주당 액면가 $0.000000000000041인 주식이 병합 후 1주당 액면가 $0.000000000000287인 주식 1주로 전환됩니다. 소수 주식은 모아져 공개 시장에서 매각되며, 현금 수익은 해당 주주들에게 배분됩니다.

모든 미결제 옵션, 워런트(예: SMXWW 포함) 및 기타 전환 증권도 비례하여 조정됩니다. 새로운 액면가를 반영한 개정 정관은 증거자료 1.1로 제출되었으며, 관련 보도자료는 증거자료 99.1로 제출되었습니다.

2025년 5월 2일 결의안으로 이사회가 자율적으로 주식 종류를 통합하거나 분할할 권한을 이미 부여받아 추가 주주 투표는 필요하지 않았습니다.

SMX (Security Matters) PLC a approuvé un regroupement d'actions inversé au ratio de 1 pour 7 de ses actions ordinaires, effectif à l'ouverture des marchés le 7 août 2025 sur le Nasdaq Capital Market. Les actions continueront d'être négociées sous le symbole SMX, mais avec un nouveau CUSIP (G8267K2174) et ISIN (IE000TB5RTG4).

Ce regroupement réduira le nombre d'actions en circulation d'environ 9 millions à environ 1 million ; chaque sept actions avant regroupement, d'une valeur nominale de 0,000000000000041 $, sera converti en une action après regroupement, d'une valeur nominale de 0,000000000000287 $. Les fractions d'actions seront regroupées et vendues sur le marché ouvert, les liquidités issues de la vente étant distribuées aux détenteurs concernés.

Toutes les options, bons de souscription (y compris SMXWW) et autres titres convertibles en circulation seront ajustés proportionnellement. Une constitution modifiée reflétant la nouvelle valeur nominale est déposée en tant qu'Exhibit 1.1, et le communiqué de presse associé en tant qu'Exhibit 99.1.

Aucun vote supplémentaire des actionnaires n'était nécessaire car une résolution du 2 mai 2025 avait déjà autorisé le conseil d'administration à consolider ou diviser les catégories d'actions à sa discrétion.

SMX (Security Matters) PLC hat eine Aktienzusammenlegung im Verhältnis 1 zu 7 seiner Stammaktien genehmigt, die ab Handelsbeginn am 7. August 2025 am Nasdaq Capital Market wirksam wird. Die Aktien werden weiterhin unter dem Ticker SMX gehandelt, erhalten jedoch eine neue CUSIP (G8267K2174) und ISIN (IE000TB5RTG4).

Die Zusammenlegung wird die ausstehenden Aktien von etwa 9 Millionen auf etwa 1 Million reduzieren; jeweils sieben Aktien vor der Zusammenlegung mit einem Nennwert von $0,000000000000041 werden in eine Aktie nach der Zusammenlegung mit einem Nennwert von $0,000000000000287 umgewandelt. Bruchteile werden gesammelt und am offenen Markt verkauft, die Erlöse werden an die betroffenen Inhaber ausgezahlt.

Alle ausstehenden Optionen, Warrants (einschließlich SMXWW) und andere wandelbare Wertpapiere werden anteilig angepasst. Eine geänderte Satzung, die den neuen Nennwert widerspiegelt, ist als Anlage 1.1 eingereicht, die zugehörige Pressemitteilung als Anlage 99.1.

Eine zusätzliche Abstimmung der Aktionäre war nicht erforderlich, da eine Resolution vom 2. Mai 2025 den Vorstand bereits ermächtigt hatte, Aktienklassen nach eigenem Ermessen zusammenzulegen oder zu teilen.

0001831828false00018318282025-08-052025-08-05

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2025

 

 

Vera Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

001-40407

81-2744449

(State or other jurisdiction
of incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

2000 Sierra Point Parkway, Suite 1200

 

Brisbane, California

 

94005

(Address of principal executive offices)

 

(Zip Code)

 

(650) 770-0077

Registrant’s telephone number, including area code
 

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Class A common stock, $0.001 par value per share

 

VERA

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


 

Item 2.02 Results of Operations and Financial Condition

 

On August 5, 2025, Vera Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.

Description

99.1

Press Release of Vera Therapeutics, Inc., dated August 5, 2025.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Vera Therapeutics, Inc.

 

 

 

 

Date:

August 5, 2025

By:

/s/ Sean Grant

 

 

 

Sean Grant, Chief Financial Officer

 


FAQ

When will SMX shares trade post-reverse split?

The split is effective at the open of Nasdaq trading on 7 Aug 2025.

What is the SMX reverse stock split ratio?

Every 7 ordinary shares will be combined into 1 ordinary share (7-for-1).

How many SMX shares will be outstanding after the split?

Outstanding shares will drop from approximately 9 million to about 1 million.

Will SMX issue fractional shares?

No. Fractional entitlements will be aggregated and sold, with cash proceeds distributed.

Does the reverse split affect SMX warrants (SMXWW)?

Yes. All warrants and convertible securities will be proportionally adjusted per their terms.

Was shareholder approval required for this split?

No additional vote was needed; shareholders authorized consolidations on 2 May 2025.
Vera Therapeutics, Inc.

NASDAQ:VERA

VERA Rankings

VERA Latest News

VERA Latest SEC Filings

VERA Stock Data

1.34B
60.71M
3.97%
111.53%
12.92%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRISBANE